

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Long-term effectiveness of COVID-19 vaccines, bradycardia after remdesivir, COVID-19 knowledge gaps and research priorities

Peer reviewed journals featured:

- A systematic review on long-term effectiveness of COVID-19 vaccines in adults [here](#)
- Observational studies on:
 - Pulmonary recovery from COVID-19 in patients with metabolic diseases [here](#)
 - SARS-CoV-2 variants in Beijing during 2022 [here](#) and commentary [here](#)
 - Resistance of Omicron BA.2.75.2, BA.4.6, and BQ.1.1 to neutralising antibodies [here](#)
 - Maternal mRNA vaccination during pregnancy and Delta or Omicron infection or hospital admission in infants [here](#) and associated editorial [here](#)
 - Comirnaty (Pfizer) vaccine in children younger than 5 years of age [here](#)
 - Association between vitamin D3 and thiols status and COVID-19 outcomes [here](#)
 - Real-world use of nirmatrelvir–ritonavir against Omicron variants including BA.4 and BA.5 in Colorado [here](#) associated commentary [here](#)
 - Viral burden rebound in hospitalised COVID-19 patients on oral antivirals [here](#) and [here](#)
 - Incidence, risk, and severity of paediatric SARS-CoV-2 reinfections in Serbia [here](#)
 - Identification of bradycardia following remdesivir administration [here](#)
 - Symptoms, disability, and financial trajectories in COVID-19 inpatients at 6 months [here](#)
 - Patient safety and hospital visiting at the end of life during COVID-19 restrictions [here](#)
 - ‘Test to treat’ care delivery model in Los Angeles [here](#)
 - COVID-19 incidence and mortality in 12-year-olds by time since vaccination [here](#)
- Commentary on:
 - Coronavirus knowledge gaps and research priorities [here](#)
 - Maintaining health care innovations after the pandemic [here](#)
 - Mitigating the return of acute respiratory virus infections [here](#)

Letters and correspondence discussed:

- COVID-19 vaccination and risk of incident diabetes after COVID-19 infection [here](#)
- Antiviral and bivalent vaccine efficacy against an Omicron XBB.1.5 isolate [here](#)
- Substantial neutralisation escape by Omicron variants BQ.1.1 and XBB.1 [here](#)
- Protection against reinfection with the Omicron BA.2.75 subvariant [here](#)
- Immunologic effect of bivalent mRNA booster in patients undergoing haemodialysis [here](#)

Pre-peer review articles featured:

- SARS-CoV-2 neutralising antibodies after bivalent vs monovalent booster [here](#)
- Long COVID in US elderly patients [here](#)
- Long COVID and T cell dysregulation, inflammation, and adaptive immune responses [here](#)
- Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among highly vaccinated patients at high risk for severe disease [here](#)
- Estimating serum cross-neutralising responses to Omicron sub-lineages elicited by pre-Omicron or Omicron breakthrough infection [here](#)
- The long COVID evidence gap in the UK population [here](#)
- Impacts of COVID-19 physical distancing measures on vulnerable population groups [here](#)
- Comparison of two COVID-19 mortality measures used in the pandemic response in England [here](#)
- COVID-19-related mortality risk among people with disabilities [here](#)
- COVID-19 resurgence and intervention, vaccination, mutation, and ethnic conditions [here](#)
- Effects on mortality of shielding clinically extremely vulnerable patients in Liverpool, UK [here](#)
- Factors associated with non-invasive positive pressure ventilation (NIPPV) failure in a COVID-19 intermediate care unit [here](#)

Guidance and reports

- The World Health Organization published its weekly COVID-19 epidemiological report [here](#)
- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)

News and blogs

- WHO abandons plans for crucial second phase of COVID-origins investigation [here](#)
- WHO treaty hopes to overcome “catastrophic failures” of pandemic response [here](#)
- Australia’s future policies after “profound impact” of latest wave [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).